Actively Recruiting
International Observational Study of Bempedoic Acid and Its Single-Pill Combination with Ezetimibe for Adults with Primary Hypercholesterolemia or Mixed Dyslipidemia in Routine Clinical Practice
Led by Daiichi Sankyo · Updated on 2026-10-19
2120
Participants Needed
38
Research Sites
5 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are examining the real-world use of bempedoic acid and its fixed dose combination FDC with ezetimibe in adults with primary hypercholesterolemia both heterozygous familial and non-familial or mixed dyslipidemia. This observational study aims to better understand the risks and benefits of these treatments in Asian and Latin American populations where data is currently limited. Participants in this study are adults treated or intended to be treated with bempedoic acid or the combination pill with ezetimibe as part of their regular medical care. No drugs are administered by the study team as it is non-interventional. The study follows patients for one year after starting treatment to collect information on drug reactions and cardiovascular health. During the study, participants health data is collected, including adverse drug reactions, cardiovascular risk, cholesterol levels, inflammatory markers, and uric acid levels. Researchers will review treatment duration and any related adverse events. This follow-up lasts for one year after treatment initiation, monitoring routine clinical outcomes without additional interventions.
CONDITIONS
Brief Title
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Research Team
D
Daiichi Sankyo Contact for Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here